Diagnostics

Teal Health's FDA-authorized Teal Wand is now available in all 50 states, aiming to revolutionize preventive care for millions of overdue women.

Health tech firm IMVARIA, maker of an FDA-authorized AI for lung disease, has secured strategic funding from InHealth Ventures and Labcorp to expand its reach.

A new tri-specific antibody, IM1240, safely hits cancer cells at massive doses in preclinical studies, potentially solving a key toxicity problem in immunotherapy.

A new alliance aims to replace painful biopsies with high-res biology, mapping organ rejection at the cellular level to usher in a new era of personalized care.

New data from a major Swedish study reveals SAGA Diagnostics' Pathlight test can predict colorectal cancer recurrence with remarkable accuracy, changing the game.

A new blood test in Western Canada promises to detect 59 cancers early. But with a high price tag and pending approval, it raises critical questions.

Following record financial growth, RadNet promotes four executives to accelerate its shift toward proactive, AI-driven healthcare and expand its market dominance.

Aerospace veteran John Slattery brings his expertise to Orbis International, aiming to elevate the mission of its unique Flying Eye Hospital.

A routine prenatal screen can now detect a virus that causes birth defects, offering a path to prevention and sparking calls to change medical guidelines.

LifeVantage heads to the ICR Conference to woo investors. Can its cellular health science overcome market headwinds and a volatile direct selling landscape?

With a top neurologist at the helm and a breakthrough platform, NanoMosaic aims to decentralize brain health diagnostics and reshape drug development.

A groundbreaking Duke trial combines a novel device to lure cancer cells with targeted immunotherapy, offering real-time tracking and new hope for patients.

A new partnership aims to eliminate lab management headaches for clinics, offering a single platform for ordering, results, and personalized treatment plans.

With its rare disease drug JURVIGO® in late-stage trials, Mezzion appoints a veteran leader to navigate the path to approval and commercialization.

With its massive data library and AI platforms, Tempus AI prepares for a pivotal presentation. What will CEO Eric Lefkofsky reveal to investors?

Bio-Rad's leadership will meet investors at the J.P. Morgan conference, facing questions on strategy and growth in a competitive, tech-driven market.

Inspira Technologies announces a landmark deal to acquire a liquid biopsy firm, securing a $15M investment at a $180M valuation to enter the cancer market.

Following a period of mixed financials, Neogen appoints new leaders to drive innovation and growth in its critical global food safety division.

A new joint venture between Corewell Health and Quest Diagnostics aims to reshape lab services across Michigan with a new high-tech facility and new efficiencies.

A new health initiative aims to fight chronic disease with personalized nutrition. But can data from your body truly fix a broken food system?